Catabasis Pharmaceuticals
14
0
0
13
Key Highlights
Risk & Performance
Pipeline Risk Assessment
Pipeline Risk Assessment
Based on historical performance
Moderate Risk
Score: 45/100
7.1%
1 terminated/withdrawn out of 14 trials
92.9%
+6.4% vs industry average
14%
2 trials in Phase 3/4
15%
2 of 13 completed trials have results
Key Signals
Enrollment Performance
Analytics
Activity Timeline
Global Presence
Clinical Trials (14)
Phase 1/2 Study in Boys With Duchenne Muscular Dystrophy
Role: lead
Phase III Study of Edasalonexent in Boys With Duchenne Muscular Dystrophy
Role: lead
Study of Edasalonexent With Midazolam and Deflazacort in Healthy Subjects
Role: lead
A 2-Part, Phase 1, Single and Multiple Ascending Dose Study to Assess the Safety, Pharmacokinetics, and Pharmacodynamics of CAT-2054 in Healthy Subjects
Role: lead
An Open-Label Extension Study of Edasalonexent in Boys With Duchenne Muscular Dystrophy
Role: lead
Your Voice; Impact of Duchenne Muscular Dystrophy (DMD) on the Lives of Families
Role: collaborator
A Study to Assess the Safety and Efficacy of CAT-2054 in Combination With Atorvastatin in Patients With Hypercholesterolemia
Role: lead
Pilot Study To Assess CAT-2003 in Patients With Hyperlipidemia
Role: lead
Pilot Study To Assess CAT-2003 in Patients With Chylomicronemia
Role: lead
Pilot Study To Assess CAT-2003 in Patients With Severe Hypertriglyceridemia
Role: lead
A Single and Multiple Ascending Dose Study to Assess the Safety, Pharmacokinetics and Pharmacodynamics of CAT-2003
Role: lead
A Study of CAT-1004 Biomarkers in Healthy Subjects
Role: lead
A Multiple Ascending Dose Study of CAT-1004 in Patients With Type 2 Diabetes
Role: lead
Safety, Tolerability, and Pharmacokinetic Study of CAT-1004 in Healthy Adult Volunteers
Role: lead
All 14 trials loaded